-
1
-
-
0024563683
-
Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma
-
Peeling WB: Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 33(suppl): 45-52, 1989.
-
(1989)
Urology
, vol.33
, Issue.SUPPL.
, pp. 45-52
-
-
Peeling, W.B.1
-
2
-
-
0021721387
-
Leuprolide versus diethylstilbestrol for metastatic prostate cancer
-
The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311: 1281-1286, 1984.
-
(1984)
N Engl J Med
, vol.311
, pp. 1281-1286
-
-
-
3
-
-
0026687613
-
Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer
-
Matzkin H, Eber P, Todd B, Van der Zwaag R, and Soloway M: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 70: 2302-2309, 1992.
-
(1992)
Cancer
, vol.70
, pp. 2302-2309
-
-
Matzkin, H.1
Eber, P.2
Todd, B.3
Van Der Zwaag, R.4
Soloway, M.5
-
4
-
-
0026525245
-
The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
-
Miller JI, Ahmann FR, Drach GW, Emerson SS, and Bottaccini MR: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147: 956-961, 1992.
-
(1992)
J Urol
, vol.147
, pp. 956-961
-
-
Miller, J.I.1
Ahmann, F.R.2
Drach, G.W.3
Emerson, S.S.4
Bottaccini, M.R.5
-
5
-
-
0027479818
-
Prostate cancer: Primary hormonal treatment
-
Denis L: Prostate cancer: primary hormonal treatment. Cancer 71(suppl): 1050-1058, 1993.
-
(1993)
Cancer
, vol.71
, Issue.SUPPL.
, pp. 1050-1058
-
-
Denis, L.1
-
6
-
-
0027998956
-
Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma
-
Karling P, Hammer M, and Varenhorst E: Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 152: 1170-1173, 1994.
-
(1994)
J Urol
, vol.152
, pp. 1170-1173
-
-
Karling, P.1
Hammer, M.2
Varenhorst, E.3
-
7
-
-
0024555272
-
Patient's choice of treatment in stage D prostate cancer
-
Cassileth BR, Soloway MS, Vogelzang PS, Seidmon EJ, Hait HI, and Kennealey GT: Patient's choice of treatment in stage D prostate cancer. Urology 33(suppl): 57-62, 1989.
-
(1989)
Urology
, vol.33
, Issue.SUPPL.
, pp. 57-62
-
-
Cassileth, B.R.1
Soloway, M.S.2
Vogelzang, P.S.3
Seidmon, E.J.4
Hait, H.I.5
Kennealey, G.T.6
-
8
-
-
0027479819
-
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma
-
Soloway MS, and Matzkin H: Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer 71(suppl): 1083-1088, 1994.
-
(1994)
Cancer
, vol.71
, Issue.SUPPL.
, pp. 1083-1088
-
-
Soloway, M.S.1
Matzkin, H.2
-
9
-
-
33646329223
-
A double-blind randomized study of primary treatment for stage D2 prostate cancer: Diethylstilbestrol (DES) vs flutamide (F)
-
abstract 21
-
Chang A, Yeap B, Blum R, Hahn R, Khanna O, Fisher H, Witte R, and Trump D: A double-blind randomized study of primary treatment for stage D2 prostate cancer: diethylstilbestrol (DES) vs flutamide (F) (abstract). Proc Annu Meet Am Soc Clin Oncol 11: abstract 21, 1992.
-
(1992)
Proc Annu Meet Am Soc Clin Oncol
, vol.11
-
-
Chang, A.1
Yeap, B.2
Blum, R.3
Hahn, R.4
Khanna, O.5
Fisher, H.6
Witte, R.7
Trump, D.8
-
10
-
-
0028886697
-
Single-agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma
-
Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, and Kennealey GT: Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 46: 849-855, 1995.
-
(1995)
Urology
, vol.46
, pp. 849-855
-
-
Chodak, G.1
Sharifi, R.2
Kasimis, B.3
Block, N.L.4
Macramalla, E.5
Kennealey, G.T.6
-
11
-
-
0025975824
-
Physiologic basis of endocrine therapy for prostatic cancer
-
McConnell JD: Physiologic basis of endocrine therapy for prostatic cancer. Urol Clin North Am 18: 1-13, 1991.
-
(1991)
Urol Clin North Am
, vol.18
, pp. 1-13
-
-
McConnell, J.D.1
-
12
-
-
0022639044
-
Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues
-
Simard J, Luthy I, Belanger A, and Labrie F: Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44: 261-270, 1986.
-
(1986)
Mol Cell Endocrinol
, vol.44
, pp. 261-270
-
-
Simard, J.1
Luthy, I.2
Belanger, A.3
Labrie, F.4
-
13
-
-
23444459401
-
Finasteride
-
Rittmaster RS: Finasteride. N Engl J Med 330: 120-125, 1994.
-
(1994)
N Engl J Med
, vol.330
, pp. 120-125
-
-
Rittmaster, R.S.1
-
14
-
-
0026806486
-
The effect of finasteride in men with benign prostatic hyperplasia
-
Gormley GL, Stoner E, Bruskewitz B, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JV, et al: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185-1191, 1992.
-
(1992)
N Engl J Med
, vol.327
, pp. 1185-1191
-
-
Gormley, G.L.1
Stoner, E.2
Bruskewitz, B.3
Imperato-McGinley, J.4
Walsh, P.C.5
McConnell, J.D.6
Andriole, G.L.7
Geller, J.8
Bracken, B.R.9
Tenover, J.V.10
-
15
-
-
0026644386
-
Multicenter, randomized double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer
-
Presti JC, Fair WR, Andriole GL, Sogani PC, Seidmon EJ, Ferguson D, Ng J, and Gormley GJ: Multicenter, randomized double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 148: 1201-1204, 1992.
-
(1992)
J Urol
, vol.148
, pp. 1201-1204
-
-
Presti, J.C.1
Fair, W.R.2
Andriole, G.L.3
Sogani, P.C.4
Seidmon, E.J.5
Ferguson, D.6
Ng, J.7
Gormley, G.J.8
-
16
-
-
0028843851
-
Treatment with finasteride following radical prostatectomy for prostate cancer
-
Andriole GL, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, DeKernion J, Rajfer J, Boake R, Crawford D, et al: Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 45: 491-497, 1995.
-
(1995)
Urology
, vol.45
, pp. 491-497
-
-
Andriole, G.L.1
Lieber, M.2
Smith, J.3
Soloway, M.4
Schroeder, F.5
Kadmon, D.6
DeKernion, J.7
Rajfer, J.8
Boake, R.9
Crawford, D.10
-
17
-
-
0026449007
-
Sequential androgen blockade: A biological study in the inhibition of prostatic growth
-
Fleshner NE, and Trachtenberg J: Sequential androgen blockade: a biological study in the inhibition of prostatic growth. J Urol 148: 1928-1931, 1992.
-
(1992)
J Urol
, vol.148
, pp. 1928-1931
-
-
Fleshner, N.E.1
Trachtenberg, J.2
-
18
-
-
0027500026
-
Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of flutamide and 4-MA
-
Martel C, Claude T, Couet J, Labrie C, Belanger A, and Labrie F: Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of flutamide and 4-MA. Mol Cell Endocrinol 91: 43-49, 1993.
-
(1993)
Mol Cell Endocrinol
, vol.91
, pp. 43-49
-
-
Martel, C.1
Claude, T.2
Couet, J.3
Labrie, C.4
Belanger, A.5
Labrie, F.6
-
19
-
-
0027879182
-
Serum PSA after antiandrogen therapy
-
Petros J, and Andriole GL: Serum PSA after antiandrogen therapy. Urol Clin North Am 20: 749-756, 1993.
-
(1993)
Urol Clin North Am
, vol.20
, pp. 749-756
-
-
Petros, J.1
Andriole, G.L.2
-
20
-
-
0025648064
-
Prognostic significance of prostate specific antigen in endocrine treatment for prostate cancer
-
Arai Y, Yoshiki T, and Yoshida O: Prognostic significance of prostate specific antigen in endocrine treatment for prostate cancer. J Urol 144: 1415-1419, 1990.
-
(1990)
J Urol
, vol.144
, pp. 1415-1419
-
-
Arai, Y.1
Yoshiki, T.2
Yoshida, O.3
-
21
-
-
0026761709
-
Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma
-
Zanetti G, Trinchieri A, Del Nero A, Montanari E, Cogni M, Colombo F, Buzzetti V, and Austoni E: Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma. Eur Urol 22(suppl): 96-98, 1992.
-
(1992)
Eur Urol
, vol.22
, Issue.SUPPL.
, pp. 96-98
-
-
Zanetti, G.1
Trinchieri, A.2
Del Nero, A.3
Montanari, E.4
Cogni, M.5
Colombo, F.6
Buzzetti, V.7
Austoni, E.8
-
22
-
-
0028799960
-
Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side effects
-
Fleshner NE, and Trachtenberg J: Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 154: 1642-1646, 1995.
-
(1995)
J Urol
, vol.154
, pp. 1642-1646
-
-
Fleshner, N.E.1
Trachtenberg, J.2
-
23
-
-
33646275441
-
Finasteride and flutamide as potency-sparing androgen ablative therapy for advanced prostate cancer
-
Brufsky A, Fontaine-Rothe P, Berlane IK, Kaplan I, and Kantoff P: Finasteride and flutamide as potency-sparing androgen ablative therapy for advanced prostate cancer. Proc Am Soc Clin Oncol 15: 252, 1996.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
, pp. 252
-
-
Brufsky, A.1
Fontaine-Rothe, P.2
Berlane, I.K.3
Kaplan, I.4
Kantoff, P.5
-
24
-
-
0024324367
-
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
-
Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
-
(1989)
N Engl J Med
, vol.321
, pp. 419-424
-
-
Crawford, E.D.1
Eisenberger, M.A.2
McLeod, D.G.3
Spaulding, J.T.4
Benson, R.5
Dorr, F.A.6
Blumenstein, B.A.7
Davis, M.A.8
Goodman, P.J.9
-
25
-
-
0028864735
-
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer
-
Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, and Kolvenbag G: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745-752, 1995.
-
(1995)
Urology
, vol.45
, pp. 745-752
-
-
Schellhammer, P.1
Sharifi, R.2
Block, N.3
Soloway, M.4
Venner, P.5
Patterson, A.L.6
Sarosdy, M.7
Vogelzang, N.8
Jones, J.9
Kolvenbag, G.10
|